The marrow hematopoietic stem cell is currently being redefined as to all aspects of its phenotype and its total differentiation capacity. This redefinition now includes its plasticity as to production of nonhematopoietic and hematopoietic cell types, the determinants of its in vivo engraftment potential and its expression of stem cell functional characteristics. Bone Marrow Transplantation (2003) 32, S19-S22. doi:10.1038/sj.bmt.1703938 Keywords: stem cell; progenition cell cycle
The marrow pluripotent stem cell has been defined by its ability to engraft and restore in vivo hematopoiesis in lethally irradiated mice. Dogma has held that space must be cleared for engraftment to occur. This view has strongly influenced many investigators' approaches to the study of stem cell biology. This view is, however, simply wrong. In a series of definitive manuscripts, we have shown that essentially all stem cells engraft in a nontreated host mouse model and that the final donor host chimerism is simply determined by the ratio of donor-to-host stem cells. 1, 2 If host stem cell are reduced by cytotoxic therapy, then there will be a higher percentage of donor stem cells and their progeny. 3 We were not the first to report engraftment in nonmyeloablated mice. Although interpretations of results may have differed, Micklem et al 4 reported similar data in the 1960s and Brecher et al, 5 subsequently, using higher cell levels, showed that significant engraftment could be obtained. We modeled our studies on those of Brecher et al. 5 We subsequently showed that therapy that would selectively reduce host stem cells without impacting significantly on marrow cellularity would markedly increase donor chimerism and allow for a reduction in the number of donor marrow cells necessary for engraftment. Exposure of mice to 100 cGy proved to be an ideal nonmyeloablative/stem cell ablative regimen. 3 Thus, high levels of chimerism could be obtained without toxicity in a syngeneic setting. This approach could be extended to allogeneic transplantation with the addition of a tolerizing treatment, initially the use of antigen pre-exposure and administration of anti-CD40 ligand antibody in the peritransplant period. 6 More recent studies have allowed for the omission of irradiation and the reduction of CD40 ligand antibody in an H2-mismatched murine transplant when the administration of marrow cells was scheduled over time. 7 These concepts are presented schematically in Figure 1 .
These approaches formed a base for the current wave of nonmyeloablative treatments, probably first published by Kolb et al 8 and effectively followed up by others. [9] [10] [11] We have used our murine engraftment studies as a base for treating resistant cancers using 100 cGy whole body irradiation and infusion of mixtures of CD3 T cells and CD34+ peripheral blood cells in both HLA-matched and haplo-identical transplants. 12, 13 Encouraging results with complete remissions have been obtained in patients with refractory marrow malignancies.
Cell cycle relation to stem cell phenotype
We initially observed that treatment of BALB/c marrow cells with IL-3, IL-6, IL-11 and steel factor in gene therapy hosts treated with anti-CD40L mAb given IP on day À10, À3, and 0. Hosts were infused with 40 million B6.SJL marrow cells on day 0. Peripheral blood chimerism was determined using FACS, staining with a CD45.1 antibody. There were 4-5 mice per group. High levels of chimerism were achieved only with anti-CD40L treatment. Long-lasting multilineage chimerism (up to 52 weeks) was seen in repetitive transplantation. Three vs five doses of CD40L had little impact on the outcomes. experiments gave high levels of MDR retroviral gene incorporation into in vitro assayed progenitors but gave very poor in vivo gene transfer.
14 Engraftment of nontransfected cells, however, was reasonably good. Subsequent studies showed that the cytokine treatment at 48 h led to a marked loss of engraftment of marrow stem cells. 15, 16 This led to studies mapping the cell cycle transit of purified lineage negative, Lin( À ), rhodamine low, Hoechst low (LRH) stem cells and following engraftment through cycle of marrow cells stimulated with the above cytokines. 17 We found that marrow cells lost engraftment in a reversible fashion and that this loss of engraftment occurred before the first cell doubling. We were able to map the loss of engraftment to late S/early G2 with a recovery of engraftment in the next G1. 18 Studies with whole marrow populations were confirmed with LRH cells. 19 Further studies showed marked modulation of adhesion protein and cytokine receptor expression with cell cycle transit. 20, 21 VLA4 was downmodulated at the time of poor engraftment and poor marrow homing. The latter was shown by a direct homing assay using cytokine-incubated CFDA-SE labeled Lin(À1) Sca-1(+) cells and assessing marrow fluorescent events 3 hours after cell infusion. These data suggested the following sequence of events when marrow stem cells were exposed to IL-3, IL-6, IL-1, and steel factor: induction of progress through cell cycle, modulation of adhesion receptors in turn altering homing which then alters engraftment. This is presented in Figure 2 .
Further cytokine or cell cycle related alterations in stem cell phenotype were observed. We noted the induction of long membrane pseudopodia, which we termed proteopodia, and which appeared to mediate the directed movement of stem cells to stromal cells. 22 These were expressed under the influence of SDF-1 and steel factor, although they were not studied at discrete points in cell cycle. We evaluated LRH gene expression utilizing a gene display technique and, comparing LRH to lineage positive marrow cells, we detected 637 stem cell-specific genes in LRH and showed a dramatic inversion of gene expression after 48 h in IL-3, IL-6, IL-11, and steel factor. 19 More recently, we have observed stem cell progenitor inversions during cell cycle transit. 23 In these experiments, we evaluated cell cycle progression, engraftable stem cell content and progenitor content of marrow cells stimulated by thrombopoietin, steel factor, and Flt3. These studies were carried out in both nonadherent Teflon bottles and in microgravity rotating wall culture vessels. We again found a fluctuation of engraftable stem cells that was reversible within the first cell cycle. We also observed that progenitors fluctuated in an inverse fashion to the fluctuation seen with the engraftable stem cells. In 20 instances, there was a marked and reversible increase in progenitors during the first cell cycle transit prior to cell division. In 19 of these 20 instances, there was a marked decrease in engraftment capacity of the same cell population. We have termed this phenomenon an inversion and feel it speaks strongly to the primitive stem cell system being a continuum rather than a hierarchy. This concept is summarized in Figure 3 .
Marrow cell homing and transdifferentiation to nonhematopoietic cells and tissues
As noted above, we have established a homing assay using CFDA-SE labeled cells. 24 Testing infused Lin( À ) Sca-1(+) cells 3 hours after infusion, we found that 48 hours of culture in IL-3, IL-6, IL-11, and steel factor resulted in a profound decrease in the ability of these cells to home to marrow. We have now assessed the ability of these cells to home to other tissues including spleen, liver, heart, brain, and lung.
We have also been evaluating the ability of marrow cells to produce cells in vivo in nonhematopoietic tissues. We have published studies in which we evaluated the capacity of male marrow cells to produce bone cells in female mice. Here, we used fluorescence in-situ-hybridization with a painting probe for repetitive sequences on the Y chromosome. 25 This is perhaps the definitive marking system. If appropriately thick sections are employed (5 mm), this is a highly reliable technique, but it is labor and reagent intensive. We have also employed a green-fluorescent protein expressing transgenic on a C57Bl background and evaluated the ability of these cells, either previously engrafted and mobilized with G-CSF or immediately infused, to give rise to GFP-positive events in different nonhematopoietic tissues and to give rise to nonhematopoietic cells in those tissues. In these studies, we have Figure 2 Homing defect of cytokine-cultured purified hematopoietic stem cells. Lineage-Sca-1+ cells were labeled with CFDA-SE and homed for 3 h. The percentage of fluorescent cells was assessed by high-speed FACS analysis of bone marrow. When stem cells were cultured for 48 h in IL-3, IL-6, IL-11, and steel factor, a marked decrease of homing was observed in a total of five experiments.
Single cell cycle Figure 3 Inversion phenotype of early hematopoietic stem cells. While traveling through cell cycle, stem cell acquire a progenitor phenotype (as measured by 7-factor HPP-CFC assay) and lose their stem cell phenotype (as measured by the engraftment capacity at 8 weeks). This phenomenon was mapped to late S early G2 and was reversible by the next G1. evaluated skin wounding as an injury for skin with and without local irradiation and irradiation and carbon tetrachloride for liver injury. 26, 27 First, we have found many fluorescent events in many tissues including lung, brain, heart, skeletal muscle, and blood vessels. Early, many of these events are CD45-positive inflammatory cells, but later we see nonhematopoietic cells and structures that are GFP positive. Thus far, we have identified GFPpositive hepatocytes, which also stain for CD26 and albumiun and cytokeratin GFP-positive cells in the skin. Perhaps more impressively, we have noted virtual replacement of host with donor GFP-positive cells in hair follicles and sebaceous glands. We have also observed a GFP-positive hair.
In recent studies, we have exposed host mice to 1000 cGy brain irradiation and infused them with GFP-positive marrow. One month later there are many positive brain fluorescent events, many of which appear to be nonhematopoietic neural cells. In general, these studies have indicated that the type and degree of organ injury is critical for observing the transdifferentiation phenomena. The mode of delivery, that is, previous established chimerism with mobilization or direct cell infusion, is also important, as is the timing of evaluation. In most cases, longer time intervals from cell infusion appear to give higher degrees of transdifferentiation. The details are probably critical. There will probably be very different injury regimens, cell thresholds, and optimum delivery modes and time courses for different tissues. We have not yet tested whether transdifferentiation varies with cell cycle.
Conclusion
The above indicates that primitive hematopoiesis rather than being a hierarchical system is a continuum. The phenotype of the primitive 'origin cells' shifts from that of an engraftable stem cell to multifactor responsive progenitor and back depending on the phase of cell cycle and these are not differentiation events. These shifts are probably dependent on continuing chromatin remodeling with cycle transit and differential expression of different cell surface receptors. We hypothesize that the capacity of marrow 'origin' cells to transdifferentiate in nonhematopoietic tissues will also demonstrate cell cycle related phenotypic shifts.
